NEW_CURA-LEAF_1170x120_OCT

Upsher-Smith adds Zembrace SymTouch (sumatriptan) Injection to program

Print Friendly, PDF & Email
MAPLE GROVE, Minn. — Upsher-Smith announced Monday that it has added Zembrace SymTouch (sumatriptan) Injection 3 mg to its Access Pathways Platinum Pass Program – a savings and support program where eligible patients pay $0 per prescription. Zembrace SymTouch is indicated for the acute treatment of migraine with or without aura in adults. It provides migraine pain relief in as little as 10 minutes for some patients. Zembrace SymTouch joins Qudexy XR (topiramate) Extended-Release Capsules and Tosymra (sumatriptan) Nasal Spray as part of Upsher-Smith’s portfolio of medications  supported by the program.

Rusty Field

The Access Pathways Program is a best-in-class co-pay program designed to reduce out-of-pocket costs for patients and improve prescribing confidence for healthcare professionals. The benefits of the Platinum Pass savings card for Zembrace SymTouch include:

  • $0 Co-Pay Offer for Eligible Patients*: The offer covers a maximum of eight single-use injections per month and is available at pharmacies nationwide.
  • Easy Enrollment. Patients can activate their Platinum Pass savings card by calling 1-855-699-6062 or online at http://www.zembrace.com/patient-savings/.
  • Renewable Annually. The Platinum Pass is good for one year and can be renewed on an annual basis.

“Minutes matter to migraine patients who are seeking fast pain relief,” said Rusty Field, president and chief executive officer, Upsher-Smith. “By adding fast-acting Zembrace SymTouch to the Access Pathways Program, we are able to assist patients by reducing some of the barriers associated with access and affordability, along with challenges that healthcare professionals face when prescribing.”


EMC_728x90

CURA_728x90_8-22-19

Comments are closed.